Trial · NCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT07583563, Recruiting, Camurus AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly. Trials, record NCT07583563. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07583563
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
- NCT number
- NCT07583563
- Status
- Recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Camurus AB
- Conditions
- Acromegaly
- Interventions
- Octreotide subcutaneous depot
- First posted
- 2026-05-13
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information. | From enrollment to the end of treatment at 2 years | |
| Secondary | Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time. | From enrollment to the end of treatment at 2 years | |
| Secondary | Change in proportion of participants with IGF-1 ≤1×ULN over time. | From enrollment to the end of treatment at 2 years | |
| Secondary | Change in GH levels over time. | From enrollment to the end of treatment at 2 years | |
| Secondary | Change in proportion of participants with GH levels <1.0 μg/L over time. | From enrollment to the end of treatment at 2 years | |
| Secondary | Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale. | From enrollment to the end of treatment at 2 years | The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
| Secondary | Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL). | From enrollment to the end of treatment at 2 years | The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
| Secondary | Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM). | From enrollment to the end of treatment at 2 years | The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
| Secondary | Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire. | From enrollment to the end of treatment at 2 years | The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
| Secondary | Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale. | From enrollment to the end of treatment at 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07583563
GET https://conductscience.org/api/trials/v1/NCT07583563/registered